herb · for poor memory
Bacopa
Its active compounds support the messenger your brain uses to lay down memories.
Say that in clinical terms
Bacosides enhance memory consolidation and acetylcholine neurotransmission, improving learning and recall.
How strong is the research?
Mixed evidence
A 12-week trial in 87 adults with memory complaints found no improvement.
5 papers read, 4 supporting, 1 against.
Who was studied: Mostly adults, tilting older. A moderate match.
How much to take
daily
300–600 mg
Standardized to 50% bacosides. Full effects at 12 weeks. Take with fat for absorption.
Before you take it
- In vitro studies show Bacopa monnieri non-competitively inhibits CYP1A2, CYP2C9, and CYP2C19, and competitively inhibits CYP3A4; at gut concentrations modeled on 300 mg/day dosing, CYP3A4, CYP2C9, and CYP2C19 activity is reduced to <10% of baseline — clinically significant herb-drug interaction risk for medications metabolized by these enzymes, including warfarin, statins, SSRIs, antiepileptics, and benzodiazepines.
- Acetylcholinesterase inhibitor activity: may potentiate cholinergic drugs (risk of cholinergic excess/toxicity) and antagonize anticholinergic medications; a published case report describes malaise, nausea, and tachycardia attributed to a Bacopa–cevimeline interaction.
- Animal data (mice) show approximately 40% increase in circulating thyroxine (T4) following Bacopa monnieri administration; caution warranted in individuals with thyroid disorders or taking thyroid medications.
- The most commonly reported adverse effects are nausea, increased stool frequency, and abdominal cramps, particularly when taken on an empty stomach.
- No NIH/IOM Tolerable Upper Intake Level (UL) has been established for Bacopa monnieri.
- Insufficient clinical safety data exist for use during pregnancy or lactation; avoidance during these periods is generally recommended.
- Cholinergic mechanism of action may worsen bradycardia, gastrointestinal obstruction, peptic ulcer disease, asthma, or COPD.
- Animal studies report dose-dependent reductions in male sperm count, motility, and viability; reproductive safety in human males is not established from clinical data.
What we make of it
A real analysis, but the gains found were narrow.
The detail
The pooled review is real and properly cited. What it found was statistically narrow — improvements on specific measures rather than memory broadly.